Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 3 de 3
Filtrer
1.
Mol Cancer ; 10: 123, 2011 Sep 28.
Article de Anglais | MEDLINE | ID: mdl-21955618

RÉSUMÉ

PURPOSE: There are conflicting reports regarding the function of EFEMP1 in different cancer types. In this study, we sought to evaluate the role of EFEMP1 in malignant glioma biology. EXPERIMENTAL DESIGN: Real-time qRT-PCR was used to quantify EFEMP1 expression in 95 glioblastoma multiforme (GBM). Human high-grade glioma cell lines and primary cultures were engineered to express ectopic EFEMP1, a small hairpin RNA of EFEMP1, or treated with exogenous recombinant EFEMP1 protein. Following treatment, growth was assayed both in vitro and in vivo (subcutaneous (s.c.) and intracranial (i.c.) xenograft model systems). RESULTS: Cox regression revealed that EFEMP1 is a favorable prognostic marker for patients with GBM. Over-expression of EFEMP1 eliminated tumor development and suppressed angiogenesis, cell proliferation, and VEGFA expression, while the converse was true with knock-down of endogenous EFEMP1 expression. The EFEMP1 suppression of tumor onset time was nearly restored by ectopic VEGFA expression; however, overall tumor growth rate remained suppressed. This suggested that inhibition of angiogenesis was only partly responsible for EFEMP1's impact on glioma development. In glioma cells that were treated by exogenous EFEMP1 protein or over-expressed endogenous EFEMP1, the EGFR level was reduced and AKT signaling activity attenuated. Mixing of EFEMP1 protein with cells prior to s.c. and i.c. implantations or injection of the protein around the established s.c. xenografts, both significantly suppressed tumorigenicity. CONCLUSIONS: Overall, our data reveals that EEFEMP1 suppresses glioma growth in vivo, both by modulating the tumor extracellular microenvironment and by altering critical intracellular oncogenic signaling pathways.


Sujet(s)
Marqueurs biologiques tumoraux/métabolisme , Tumeurs du cerveau/métabolisme , Prolifération cellulaire , Protéines de la matrice extracellulaire/métabolisme , Espace extracellulaire/métabolisme , Glioblastome/métabolisme , Animaux , Marqueurs biologiques tumoraux/génétique , Marqueurs biologiques tumoraux/pharmacologie , Tumeurs du cerveau/vascularisation , Tumeurs du cerveau/anatomopathologie , Lignée cellulaire tumorale , Récepteurs ErbB/métabolisme , Protéines de la matrice extracellulaire/génétique , Protéines de la matrice extracellulaire/pharmacologie , Femelle , Techniques de knock-down de gènes , Glioblastome/vascularisation , Glioblastome/anatomopathologie , Humains , Estimation de Kaplan-Meier , Souris , Souris nude , Transplantation tumorale , Protéines proto-oncogènes c-akt/métabolisme , Interférence par ARN , Protéines recombinantes/génétique , Protéines recombinantes/métabolisme , Protéines recombinantes/pharmacologie , Transduction du signal , Charge tumorale
2.
J Neurooncol ; 96(2): 191-200, 2010 Jan.
Article de Anglais | MEDLINE | ID: mdl-19618119

RÉSUMÉ

We reported that PAX6 suppresses glioblastoma cell growth in vivo and anchorage-independent growth without significant alteration of cell proliferation in vitro, suggesting that PAX6 may alter the tumor microenvironment. Because we found that PAX6 downregulates expression of the gene encoding vascular endothelial growth factor A (VEGFA) in glioma cells, we used a subcutaneous xenograft model to verify PAX6 suppression of VEGFA-induced angiogenesis based on CD31-immunostaining of endothelial cells. The results showed a significant reduction of VEGFA at the transcription level in PAX6-transfected cells in xenografts and PAX6 has a suppressive effect on the microvascular amplification typically seen in glioblastoma. We showed that PAX6 suppression of VEGFA expression requires its DNA binding-domain. The C-terminal truncation mutant of PAX6, however, did not show the dominant negative function in regulating VEGFA expression that it showed previously in regulating MMP2 expression. In the glioma cell line U251HF, we further determined that blocking the PI3K/Akt signaling pathway with either adenoviral-mediated PTEN expression or LY294002 enhanced PAX6-mediated suppression of VEGFA in an additive manner; thus, PAX6-mediated suppression of VEGFA is not via the canonical pathway through HIF1A. These two VEGFA-regulatory pathways can also be similarly modulated in another malignant glioma cell line, U87, but not in LN229 where the basal VEGFA level is low and PTEN is wild-type. PAX6 suppression of VEGFA appears to be blocked in LN229. In conclusion, our data showed that PAX6 can initiate in glioma cells a new signaling pathway independent of PI3K/Akt-HIF1A signaling to suppress VEGFA expression.


Sujet(s)
Régulation de l'expression des gènes tumoraux/génétique , Néovascularisation pathologique/physiopathologie , Facteur de transcription PAX2/métabolisme , Facteur de croissance endothéliale vasculaire de type A/métabolisme , Analyse de variance , Animaux , Lignée cellulaire tumorale , 4H-1-Benzopyran-4-ones/pharmacologie , Antienzymes/pharmacologie , Test ELISA/méthodes , Régulation de l'expression des gènes tumoraux/effets des médicaments et des substances chimiques , Gliome/anatomopathologie , Protéines à fluorescence verte/génétique , Humains , Souris , Morpholines/pharmacologie , Transplantation tumorale/méthodes , Néovascularisation pathologique/génétique , Facteur de transcription PAX2/génétique , Phosphohydrolase PTEN/génétique , Phosphohydrolase PTEN/métabolisme , Antigènes CD31/métabolisme , Transduction du signal/génétique , Transfection/méthodes , Facteur de croissance endothéliale vasculaire de type A/génétique , Tests d'activité antitumorale sur modèle de xénogreffe
3.
J Res Natl Inst Stand Technol ; 107(5): 445-73, 2002.
Article de Anglais | MEDLINE | ID: mdl-27446745

RÉSUMÉ

Pulsed ultrasonic techniques can be and have been used to examine the interface conditions of a bonded structure. To provide a theoretical basis for such testing techniques we model the structure as a layer on top of a half-space, both of different elastic properties, with various interface bonding conditions. The exact dynamic Green's tensor for such a structure is explicitly derived from the three-dimensional equations of motion. The final solution is a series. Each term of the series corresponds to a successive arrival of a "generalized ray" and each is a definite line integral along a fixed path which can be easily computed numerically. Willis' method is used in the derivation. A new scheme of automatic generation of the arrivals and ray paths using combinatorial analysis, along with the summation of the corresponding products of reflection coefficients is presented. A FORTRAN code is developed for computation of the Green's tensor when both the source and the detector are located on the top surface. The Green's tensor is then used to simulate displacements due to pulsed ultrasonic point sources of known time waveform. Results show that the interface bonding conditions have a great influence on the transient displacements. For example, when the interface bonding conditions vary, some of the first few head waves and regular reflected rays change polarities and amplitudes. This phenomenon can be used to infer the quality of the interface bond of materials in ultrasonic nondestructive evaluation. In addition the results are useful in the study of acoustic microscopy probes, coatings, and geo-exploration.

SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...